By Mill Chart
Last update: Mar 26, 2024
GILEAD SCIENCES INC (NASDAQ:GILD) has caught the attention of dividend investors as a stock worth considering. NASDAQ:GILD excels in profitability, solvency, and liquidity, all while providing a decent dividend. Let's delve into the details.
ChartMill assigns a Dividend Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing various dividend elements, such as yield, historical performance, dividend growth, and sustainability. NASDAQ:GILD has been awarded a 7 for its dividend quality:
ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NASDAQ:GILD scores a 5 out of 10:
ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NASDAQ:GILD scores a 7 out of 10:
More Best Dividend stocks can be found in our Best Dividend screener.
Our latest full fundamental report of GILD contains the most current fundamental analsysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
109.3
-0.79 (-0.72%)
Find more stocks in the Stock Screener
GILEAD SCIENCES (NASDAQ:GILD) is a high-quality biopharma stock with strong profitability, efficient capital use, and attractive valuation, making it a candidate for long-term investors.
GILEAD SCIENCES (NASDAQ:GILD) appears undervalued with strong profitability, a solid dividend, and reasonable growth potential, making it a candidate for value investors.